Laplace Deep Dive_Arbormed

G2G Bio Passes Technical Evaluation for IPO

Ingenium Therapeutics' Latest Initiative

Laplace Deep Dive_Ibex

Ingenium Therapeutics Earns Orphan Drug Status from U.S. FDA

HITS Co-Founder and CTO Jaechang Lim Named to Forbes 30 Under 30 Asia

MD Anderson Cancer Center Signs First International Contract with HITS

CEO Insoo Han Featured on SBS Biz: Insights into Laplace Partners' Investment Strategy

HITS Unveils AI Drug Discovery Platform ‘HyperLab’ at International Medicinal Chemistry Symposium

Ingenium Therapeutics Begins Phase 2 Clinical Trials in Korea